Patient characteristics
| . | ABVD + brentuximab vedotin . | AVD + brentuximab vedotin . |
|---|---|---|
| n | 25 | 26 |
| Age, y, median (range) | 35 (19-59) | 33 (18-58) |
| Male sex, n (%) | 20 (80) | 17 (65) |
| Performance status,*n (%) | ||
| 0 | 13 (52) | 11 (42) |
| 1 | 12 (48) | 15 (58) |
| Stage, n (%) | ||
| IIA bulky† | 0 | 3 (12) |
| IIB | 4 (16) | 4 (15) |
| IIIA | 5 (20) | 3 (12) |
| IVA | 4 (16) | 5 (19) |
| IVB | 12 (48) | 11 (42) |
| International Prognostic Score, n (%) | ||
| 0-3 | 5 (20) | 12 (46) |
| 4-7 | 20 (80) | 14 (54) |
| . | ABVD + brentuximab vedotin . | AVD + brentuximab vedotin . |
|---|---|---|
| n | 25 | 26 |
| Age, y, median (range) | 35 (19-59) | 33 (18-58) |
| Male sex, n (%) | 20 (80) | 17 (65) |
| Performance status,*n (%) | ||
| 0 | 13 (52) | 11 (42) |
| 1 | 12 (48) | 15 (58) |
| Stage, n (%) | ||
| IIA bulky† | 0 | 3 (12) |
| IIB | 4 (16) | 4 (15) |
| IIIA | 5 (20) | 3 (12) |
| IVA | 4 (16) | 5 (19) |
| IVB | 12 (48) | 11 (42) |
| International Prognostic Score, n (%) | ||
| 0-3 | 5 (20) | 12 (46) |
| 4-7 | 20 (80) | 14 (54) |